We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Claims Its Experimental Diabetes Drug Outperforms Ozempic
Eli Lilly Claims Its Experimental Diabetes Drug Outperforms Ozempic
Eli Lilly said its investigational drug, tirzepatide, reduced blood sugar and body weight in adults with type 2 diabetes significantly more than Novo Nordisk’s blockbuster Ozempic (semaglutide), in a head-to-head clinical study.